An overview of the types of data available can be found in the table below. For further details regarding this data please contact the Lead PI for the STOP-HCV Consortium, Professor Ellie Barnes (ellie.barnes@ndm.ox.ac.uk). Access to STOP-HCV data is via application (data request form) and requests will be reviewed by the STOP-HCV Data Access Committee.
|
Type of data
|
Patient cohort
|
|
HCV whole genome sequence data
Publications:
Thomson E et al ‘Comparison of next generation sequencing technologies for the comprehensive assessment of full-length hepatitis C viral genomes’Journal of Clinical Microbiology 2016 54 (10): 2470-84
Ansari MA, Pedergnana V et al ‘A genome-to-genome analysis shows the impact of the innate and adaptive immune system on the hepatitis C virus’Nat Genet. 2017 49(5): 666-673
Ansari MA et al “Interferon lambda 4 impacts the genetic diversity of hepatitis C virus.” Elife. 2019 Sep 3;8. pii: e42463. doi: 10.7554/eLife.42463.
Smith D et al ‘Resistance analysis of genotype 3 HCV reveals subtypes inherently resistant to NS5A inhibitors’.Hepatology. 2019 May; 69(5):1861-1872. doi: 10.1002/hep.29837. Epub 2018 Apr 27
|
BOSON study (n=601)
Foster GR et al. ‘Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection’ Gastroenterology 2015, 149(6): 1462-70
HCV Research UK (n>12,000; ~1,000 patients with HCV WGS data)
McLauchlan J et al. ‘Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.’ Int J Epidemiol. 2017 Oct 1;46(5):1391-1391h
STOP-HCV Cirrhosis Study (subset of HCV Research UK cohort; n=1,254)
NHS England Early Access DAA programme (n=806)
Foster GR, Irving WI et al. ‘Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis’. J Hepatology 2016; 64(6): 1224-1231
STOP-HCV1 (n=202)
|
|
Host genotyping data - generated using Affymetrix UK Biobank array
Publications:
Ansari MA, Pedergnana V et al ‘A genome-to-genome analysis shows the impact of the innate and adaptive immune system on the hepatitis C virus’Nat Genet. 2017 49(5): 666-673
Pedergnana V et al. ‘Impact of IFNL4 genetic variants on sustained virologic response and vireamia in hepatitis C virus genotype 3 patients’ J Interferon Cytokine Res. 2019 Jul 1. Doi: 10.1089/jir.2019.0013
Ansari MA et al “Interferon lambda 4 impacts the genetic diversity of hepatitis C virus.” Elife. 2019 Sep 3;8. pii: e42463. doi: 10.7554/eLife.42463.
|
BOSON study (n=601)
Foster GR et al. ‘Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection’ Gastroenterology 2015, 149(6): 1462-70
HCV Research UK (n>12,000; ~3,500 patients with HCV WGS data)
McLauchlan J et al. ‘Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.’ Int J Epidemiol. 2017 Oct 1;46(5):1391-1391h
STOP-HCV Cirrhosis Study (subset of HCV Research UK cohort; n=1,254)
NHS England Early Access DAA programme (n=806)
Foster GR, Irving WI et al. ‘Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis’. J Hepatology 2016; 64(6): 1224-1231
STOP-HCV1 (n=202)
|
|
RNAseq data
Publications:
Ramamurthy N et al ‘Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C’ Hepatology. 2018 Mar 13. doi: 10.1002/hep.29877
|
BOSON study (n=601; ~300 with RNAseq data)
Foster GR et al. ‘Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection’ Gastroenterology 2015, 149(6): 1462-70
|
|
Immune phenotyping data
(e.g. cytokine assays, flow cytometry, microbial translocation)
|
BOSON study (n=601)
Foster GR et al. ‘Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection’ Gastroenterology 2015, 149(6): 1462-70
|
|
Biomarker data
(e.g. GALAD scoring, mass spectrometry for fibrosis markers)
|
NHS England Early Access DAA programme (n=806; ~75 with GALAD scoring)
Foster GR, Irving WI et al. ‘Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis’. J Hepatology 2016; 64(6): 1224-1231
HCV Research UK (n>12,000; ~100 with mass spectrometry data for fibrosis markers)
McLauchlan J et al. ‘Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.’ Int J Epidemiol. 2017 Oct 1;46(5):1391-1391h
|
